Bioequivalence of Imeglimin Tablet Formulations

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is an open‐label assessment of the bioequivalence of two 500 mg‐tablet formulations of imeglimin (Tablet A [reference product] and Tablet B [test product]), in at least 16 healthy Caucasian volunteers.
Epistemonikos ID: bc828383bd20037dcf4691644256e0bdd351507b
First added on: May 21, 2024